Pediatrix Medical Group (NYSE:MD) Given New $15.00 Price Target at Truist Financial

Pediatrix Medical Group (NYSE:MD) had its target price cut by Truist Financial from $16.00 to $15.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have a hold rating on the stock.

A number of other research analysts also recently commented on MD. Mizuho increased their target price on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. Jefferies Financial Group raised their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft lifted their target price on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Macquarie initiated coverage on Pediatrix Medical Group in a research report on Monday, December 16th. They issued an “outperform” rating and a $18.00 target price for the company. Finally, UBS Group lifted their price target on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $16.25.

Pediatrix Medical Group Stock Down 2.5 %

Shares of NYSE MD opened at $12.81 on Monday. The business has a 50-day moving average of $14.35 and a two-hundred day moving average of $11.49. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -4.19, a price-to-earnings-growth ratio of 2.00 and a beta of 1.58. Pediatrix Medical Group has a 1 year low of $6.62 and a 1 year high of $16.41. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. The firm had revenue of $511.20 million during the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm’s revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.29 earnings per share. On average, analysts forecast that Pediatrix Medical Group will post 1.26 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Mark S. Ordan sold 27,600 shares of the firm’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the sale, the director now owns 138,683 shares in the company, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Mary Ann E. Moore sold 8,108 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the transaction, the executive vice president now owns 135,810 shares in the company, valued at approximately $2,172,960. This trade represents a 5.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.00% of the stock is owned by insiders.

Institutional Trading of Pediatrix Medical Group

Hedge funds have recently modified their holdings of the business. Rubric Capital Management LP grew its holdings in Pediatrix Medical Group by 1.5% during the third quarter. Rubric Capital Management LP now owns 8,275,000 shares of the company’s stock worth $95,907,000 after acquiring an additional 125,000 shares during the period. State Street Corp boosted its position in shares of Pediatrix Medical Group by 1.4% during the 3rd quarter. State Street Corp now owns 3,540,791 shares of the company’s stock worth $41,038,000 after purchasing an additional 50,597 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Pediatrix Medical Group by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,936,751 shares of the company’s stock worth $22,452,000 after purchasing an additional 45,155 shares during the period. Dana Investment Advisors Inc. increased its holdings in shares of Pediatrix Medical Group by 80.3% in the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock valued at $7,725,000 after purchasing an additional 455,785 shares in the last quarter. Finally, Weiss Asset Management LP lifted its stake in shares of Pediatrix Medical Group by 50.5% in the third quarter. Weiss Asset Management LP now owns 912,818 shares of the company’s stock valued at $10,580,000 after purchasing an additional 306,143 shares during the period. 97.71% of the stock is owned by institutional investors and hedge funds.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.